NeoGenomics (STU:NG9) COGS-to-Revenue : 0.58 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is NeoGenomics COGS-to-Revenue?

NeoGenomics's Cost of Goods Sold for the three months ended in Mar. 2024 was €83.5 Mil. Its Revenue for the three months ended in Mar. 2024 was €143.7 Mil.

NeoGenomics's COGS to Revenue for the three months ended in Mar. 2024 was 0.58.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. NeoGenomics's Gross Margin % for the three months ended in Mar. 2024 was 41.90%.

NeoGenomics COGS-to-Revenue Historical Data

The historical data trend for NeoGenomics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics COGS-to-Revenue Chart

NeoGenomics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.52

0.58

0.61

0.63

0.59

NeoGenomics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.60	0.59	0.59	0.57	0.58

NeoGenomics COGS-to-Revenue Calculation

NeoGenomics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	318.235	/	542.537
	=	0.59

NeoGenomics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	83.51	/	143.741
	=	0.58

NeoGenomics (STU:NG9) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

NeoGenomics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	83.51 / 143.741
	=	41.90 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

NeoGenomics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of NeoGenomics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NeoGenomics (STU:NG9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (STU:NG9) » Definitions » COGS-to-Revenue

Comparable Companies

VCYT MYGN TWST OPK LAB CDNA NEOG CSTL FLGT GH TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN

Traded in Other Exchanges

NEO:USA

Address

9490 NeoGenomics Way, Fort Myers, FL, USA, 33912

Website

https://www.neogenomics.com

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.

NeoGenomics (STU:NG9) Headlines

No Headlines